Article info
PDFOriginal research
Interstitial lung disease in patients treated with poly (ADP-ribose) polymerase inhibitors (PARPi): analysis of results from clinical trials and the FDA Adverse Events Reporting System database
- Correspondence to Professor Junyan Wu, Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Guangzhou, Guangdong, China; wujunyan{at}mail.sysu.edu.cn
Citation
Interstitial lung disease in patients treated with poly (ADP-ribose) polymerase inhibitors (PARPi): analysis of results from clinical trials and the FDA Adverse Events Reporting System database
Publication history
- Received September 30, 2022
- Accepted April 24, 2023
- First published May 10, 2023.
Online issue publication
October 18, 2023
Article Versions
- Previous version (7 August 2023).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ.